oa Can the Central Sympathetic Blockade Profile be Advantageous in the Management of Patients with Metabolic Syndrome?

References

1. Alberti KGMM, Zimmett P, Shaw J. for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005; 366::1059–1061.
   [Google Scholar]
2. Grassi G. Debating sympathetic overactivity as a hallmark of human obesity: A pro's position. J Hypertension. 1999; 17::1059–1060.
   [Google Scholar]
3. Zebekakis PE, Naw rot T, Balke stein EJ, Van den Heijden-Spek J, Van Bortel LM, Struijker-Boudier HA, Staessen JA. Obesity is associated with increased arterial stiffness from adolescence until old age. J. Hypertension. 2005; 23::1839–1846.
   [Google Scholar]
4. Grassi G, DelVOro R, Facchini A, Trevano FQ, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J. Hypertension. 2004; 22::2363–2369.
   [Google Scholar]
5. Reaven G. Role of insulin resistance in human disease Diabetes. 1988; 37::1595–1607.
   [Google Scholar]
6. Yusuf S, Hawken S, Oupuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. on behalf of the INTERHEART Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): Case control study. Lancet. 2004; 364::937–952.
   [Google Scholar]
7. Giles TD, Sander GE. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. J Clin Hypertens. 2005; 7:11:669–678.
   [Google Scholar]
8. Morris STW, Reid JL. Moxonidine a review. J. Human Hypertension. 1997; 11::629–635.
   [Google Scholar]
9. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertension Apr. 2005; 23:4:891–898.
   [Google Scholar]
10. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mclnnes GT, Mehlsen J, Nieminen M, O 'Brien E, Ostergren J. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet. 2005; 366:9489:895–906, Sep 10-16.
    [Google Scholar]